Role of α1-blockers in the current management of hypertension
Issued Date
2022-09-01
Resource Type
ISSN
15246175
eISSN
17517176
Scopus ID
2-s2.0-85139446011
Pubmed ID
36196467
Journal Title
Journal of Clinical Hypertension
Volume
24
Issue
9
Start Page
1180
End Page
1186
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Clinical Hypertension Vol.24 No.9 (2022) , 1180-1186
Suggested Citation
Li H., Xu T.Y., Li Y., Chia Y.C., Buranakitjaroen P., Cheng H.M., Van Huynh M., Sogunuru G.P., Tay J.C., Wang T.D., Kario K., Wang J.G. Role of α1-blockers in the current management of hypertension. Journal of Clinical Hypertension Vol.24 No.9 (2022) , 1180-1186. 1186. doi:10.1111/jch.14556 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/85542
Title
Role of α1-blockers in the current management of hypertension
Author's Affiliation
Siriraj Hospital
University Medicine and Pharmacy, Hue University
Sunway University
Jichi Medical University
Shanghai Jiao Tong University School of Medicine
Madras Institute of Orthopaedics and Traumatology Hospitals
National Taiwan University Hospital
Kathmandu University
National Yang-Ming University Taiwan
Universiti Malaya
Veterans General Hospital-Taipei
Tan Tock Seng Hospital
University Medicine and Pharmacy, Hue University
Sunway University
Jichi Medical University
Shanghai Jiao Tong University School of Medicine
Madras Institute of Orthopaedics and Traumatology Hospitals
National Taiwan University Hospital
Kathmandu University
National Yang-Ming University Taiwan
Universiti Malaya
Veterans General Hospital-Taipei
Tan Tock Seng Hospital
Other Contributor(s)
Abstract
There is emerging evidence that α1-blockers can be safely used in the treatment of hypertension. These drugs can be used in almost all hypertensive patients for blood pressure control. However, there are several special indications. Benign prostatic hyperplasia is a compelling indication of α1-blockers, because of the dual treatment effect on both high blood pressure and lower urinary tract symptoms. Many patients with resistant hypertension would require α1-blockers as add-on therapy. Primary aldosteronism screen is a rapidly increasing clinical demand in the management of hypertension, where α1-blockers are useful for blood pressure control in the preparation for the measurement of plasma aldosterone and renin. Nonetheless, α1-blockers have to be used under several considerations. Among the currently available agents, only long-acting α1-blockers, such as doxazosin gastrointestinal therapeutic system 4–8 mg daily and terazosin 2–4 mg daily, should be chosen. Orthostatic hypotension is a concern with the use of α1-blockers especially in the elderly, and requires careful initial bedtime dosing and avoiding overdosing. Fluid retention is potentially also a concern, which may be overcome by combining an α1-blocker with a diuretic.